PMID- 30070595
OWN - NLM
STAT- MEDLINE
DCOM- 20200616
LR  - 20200616
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
VI  - 25
IP  - 9
DP  - 2019 Aug
TI  - Smoking is associated with increased disease activity during natalizumab 
      treatment in multiple sclerosis.
PG  - 1298-1305
LID - 10.1177/1352458518791753 [doi]
AB  - BACKGROUND: Smoking has been associated with increased multiple sclerosis (MS) 
      risk, disease worsening, and progression in MS patients. Furthermore, 
      interactions between smoking and human leukocyte antigen (HLA) genes have been 
      shown for MS risk. Recently, we found that smoking was associated with an 
      increased relapse rate in interferon-beta-treated relapsing-remitting multiple 
      sclerosis (RRMS) patients. OBJECTIVES: We examined the association between 
      smoking and relapses in natalizumab-treated RRMS patients. Second, we 
      investigated if an interaction between smoking and HLA-DRB1*15:01 or HLA-A*02:01 
      affected the number of relapses during treatment. METHODS: In this observational 
      cohort study, 355 natalizumab-treated RRMS patients were assessed. Prespecified 
      criteria excluded 62 patients. Clinical data from the starting of treatment to 
      the two-year follow-up visit were collected. Smoking status was obtained by a 
      questionnaire survey. TaqMan allelic discrimination was used for genotyping of 
      tag single-nucleotide polymorphisms (SNPs) for HLA-DRB1*15:01 and HLA-A*02:01. 
      Negative binomial regression analysis was used to analyze the association between 
      relapse rate and smoking intensity and HLA. RESULTS: One pack of cigarettes (20 
      cigarettes) per day during natalizumab treatment increased the relapse rate 
      during treatment with 38% (incidence rate ratio (IRR) = 1.38, 95% confidence 
      interval (CI): 1.08-1.77, p = 0.01). No association or interaction was found 
      between smoking and HLA-DRB1*15:01 or HLA-A*02:01, respectively. CONCLUSION: 
      Smoking intensity was significantly associated with the number of relapses during 
      natalizumab treatment.
FAU - Petersen, Eva Rosa
AU  - Petersen ER
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Sondergaard, Helle Bach
AU  - Sondergaard HB
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Laursen, Julie Hejgaard
AU  - Laursen JH
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Olsson, Anna Gabriella
AU  - Olsson AG
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Bornsen, Lars
AU  - Bornsen L
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Soelberg Sorensen, Per
AU  - Soelberg Sorensen P
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Sellebjerg, Finn
AU  - Sellebjerg F
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      University of Copenhagen, Copenhagen, Denmark.
FAU - Bang Oturai, Annette
AU  - Bang Oturai A
AD  - Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, 
      University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20180802
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (HLA-DRB1*15:01 antigen)
RN  - 0 (Immunologic Factors)
RN  - 0 (Natalizumab)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Follow-Up Studies
MH  - HLA-A2 Antigen/genetics
MH  - HLA-DRB1 Chains/genetics
MH  - Humans
MH  - Immunologic Factors/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug therapy/genetics
MH  - Natalizumab/*therapeutic use
MH  - Polymorphism, Single Nucleotide
MH  - Recurrence
MH  - Tobacco Smoking/*adverse effects
MH  - Young Adult
OTO - NOTNLM
OT  - HLA
OT  - Natalizumab
OT  - relapse rate
OT  - smoking intensity
OT  - tobacco smoking
OT  - treatment response
EDAT- 2018/08/03 06:00
MHDA- 2020/06/17 06:00
CRDT- 2018/08/03 06:00
PHST- 2018/08/03 06:00 [pubmed]
PHST- 2020/06/17 06:00 [medline]
PHST- 2018/08/03 06:00 [entrez]
AID - 10.1177/1352458518791753 [doi]
PST - ppublish
SO  - Mult Scler. 2019 Aug;25(9):1298-1305. doi: 10.1177/1352458518791753. Epub 2018 
      Aug 2.